<DOC>
	<DOCNO>NCT00425074</DOCNO>
	<brief_summary>The purpose study evaluate platelet antiaggregant effect chronic treatment ASA ( 150 mg ) produce , compare effect two formulation ASA : normal one sustain release , patient stable coronary disease .</brief_summary>
	<brief_title>Pharmacodynamic-pharmacokinetic Trial , Slow Release ASA , Platelet Functionalism .</brief_title>
	<detailed_description>A large clinical trial establish efficacy antiaggregant product patient ischemic cardiopathy , stroke intermittent claudication . Without doubt , acetylsalicylic acid ( ASA ) use antiaggregant product , nevertheless , spite centenarian , last question pending regard appropriate dose , mechanism action implicate , association drug , pharmaceutical form order improve efficacy safety ASA . Some previous study indicate slow release form ASA different behaviour platelet effect comparison plain formulation . The aim study demonstrate best antiaggregant safety profile low dose slow release formulation ASA .</detailed_description>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Salicylates</mesh_term>
	<mesh_term>Salicylic Acid</mesh_term>
	<criteria>Previous episode myocardial infarction Previous episodes instable angina pectoris Previous coronary revascularization Significant arterial coronary disease Patients pathologies require treatment antiaggregants Patients treatment low molecular weight heparin oral anticoagulant Patients antecedent hypersensibility ASA</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>slow release ASA</keyword>
	<keyword>platelet functionalism</keyword>
	<keyword>secondary cardiovascular prevention</keyword>
</DOC>